Assessing the use of activated protein C in the treatment of severe sepsis.
D018806:APACHE; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002460:Cell Line; D002986:Clinical Trials as Topic / Q000379:methods*; D015897:Comorbidity; D017277:Drug Approval; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D011486:Protein C / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D018805:Sepsis / Q000145:classification / Q000188:drug therapy*; D016019:Survival Analysis; D014481:United States; D014486:United States Food and Drug Administration
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated